
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
EPS (Diluted)
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
SSE:600329
|
EPS (Diluted)
ÂĄ1
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
![]() |
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
ÂĄ5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
![]() |
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
ÂĄ1
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
![]() |
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
ÂĄ2
|
CAGR 3-Years
19%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
1%
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd
Glance View
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd, rooted in the rich tapestry of traditional Chinese medicine, has carved out a substantial presence in the pharmaceutical industry. Established in a region known for its deep cultural heritage in holistic healing, the company seamlessly weaves ancient practices with modern scientific advancements. At the core of its operations, Da Ren Tang specializes in the research, development, production, and distribution of traditional Chinese medicine and pharmaceuticals. Beyond just leveraging ancient recipes, the company invests significantly in cutting-edge research to validate and enhance the efficacy of its formulations, gaining trust not only domestically but also in international markets. This blending of tradition and innovation enables Da Ren Tang to capture a diverse customer base, ranging from individuals seeking natural remedies to medical institutions incorporating holistic approaches into patient care. The economic engine of Da Ren Tang powers through a multi-faceted monetization strategy. It manufactures a broad portfolio of pharmaceutical products, including patented Chinese medicines and active pharmaceutical ingredients (APIs), which are distributed through a well-established network of pharmacies and healthcare providers. Additionally, the company has embraced the digital era by exploring e-commerce platforms, thereby expanding its reach and accessibility to tech-savvy consumers globally. By maintaining stringent quality controls and adopting sustainable practices in its production processes, Da Ren Tang not only enhances its reputation but also adheres to evolving regulatory standards worldwide. Such strategic positioning allows the company to capitalize on the growing global interest in traditional medicines, contributing significantly to its revenue streams and reinforcing its status as a prominent player in the pharmaceutical landscape.

See Also
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's EPS (Diluted)?
EPS (Diluted)
1.2
CNY
Based on the financial report for Sep 30, 2024, Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's EPS (Diluted) amounts to 1.2 CNY.
What is Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
9%
Over the last year, the EPS (Diluted) growth was -5%. The average annual EPS (Diluted) growth rates for Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd have been 3% over the past three years , 9% over the past five years , and 9% over the past ten years .